Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis
* Healing of duodenal ulcers
* Reduction of risk of NSAID-associated gastric ulcers
* Zollinger-Ellison syndrome
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. Maintenance therapy: 20-40 mg once daily.
* **Duodenal Ulcers:** 40 mg orally once daily, typically for 2-4 weeks.
* **NSAID-Associated Ulcers:** 40 mg orally once daily, typically for 4-8 weeks.
* **Zollinger-Ellison Syndrome:** Starting dose 40 mg orally or intravenously once daily. Doses may be titrated up to 240 mg daily (divided every 8 hours).
## Pediatric Dosing
* **GERD (12 years and older):** 40 mg orally once daily for up to 8 weeks.
* **Erosive Esophagitis (5 years and older):** 20-40 mg orally once daily for up to 8 weeks. Dosing is weight-based for this indication, consult specific guidelines.
* **Dosing for younger children and other indications is not well-established and requires careful consideration of risk/benefit.**
## Dose Adjustments
* **Hepatic Impairment:** Maximum dose of 20 mg orally or intravenously once daily.
## Contraindications
* Hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
* **Common:** Diarrhea, headache, dizziness, abdominal pain, nausea, flatulence.
* **Serious:**
* **Long-term use:** Increased risk of fractures (hip, wrist, spine), Clostridium difficile-associated diarrhea, vitamin B12 deficiency, hypomagnesemia.
* **Acute interstitial nephritis.**
* **Systemic lupus erythematosus (new or exacerbation).**
## Key Drug Interactions
* **Clopidogrel:** Pantoprazole may decrease the antiplatelet effect of clopidogrel. Consider alternative PPIs if concomitant use is necessary or monitor patient closely.
* **Methotrexate:** Increased methotrexate levels may occur.
* **Drugs requiring gastric acid for absorption (e.g., ketoconazole, itraconazole, certain HIV protease inhibitors):** Pantoprazole may decrease absorption.
* **CYP2C19 substrates/inhibitors:** Pantoprazole is a moderate inhibitor of CYP2C19.
## Monitoring
* Electrolytes (especially magnesium with long-term use or concomitant diuretics).
* Bone mineral density with prolonged therapy.
* Renal function.
* Clinical signs and symptoms of GERD or ulcer disease.
## Clinical Pearls
* Administer oral pantoprazole at least 30 minutes before a meal.
* Do not crush or chew delayed-release tablets.
* IV administration is an option when oral route is not feasible.
* Consider the risks of long-term PPI use, especially for durations exceeding 8 weeks.
***
**Disclaimer:** This information is intended for educational purposes and does not substitute for professional medical advice. Always consult the most current prescribing information, institutional protocols, and a qualified healthcare provider for any treatment decisions.
